Elanco Animal Health Incorporated $ELAN Shares Sold by Harbor Capital Advisors Inc.

Key Points

• Harbor Capital Advisors Inc. has reduced its holdings in Elanco Animal Health by 13.8% during the second quarter, now owning about 0.16% of the company.
• Institutional investors remain active, with significant increases in holdings from Dimensional Fund Advisors and Goldman Sachs Group, among others, demonstrating strong interest in Elanco.
• Analysts generally view Elanco favorably, with a consensus rating of "Moderate Buy" and an average price target of $17.33, indicating positive market sentiment.

Harbor Capital Advisors Inc. reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 13.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 772,062 shares of the company's stock after selling 124,092 shares during the period. Harbor Capital Advisors Inc. owned 0.16% of Elanco Animal Health worth $11,025,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Elanco Animal Health by 14.3% in the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after acquiring an additional 2,563,740 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Elanco Animal Health by 1.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company's stock valued at $167,826,000 after buying an additional 292,655 shares in the last quarter. Nuveen LLC acquired a new position in Elanco Animal Health during the first quarter valued at approximately $115,212,000. Goldman Sachs Group Inc. lifted its position in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Finally, Douglas Lane & Associates LLC lifted its position in Elanco Animal Health by 5.6% during the first quarter. Douglas Lane & Associates LLC now owns 3,895,190 shares of the company's stock valued at $40,899,000 after buying an additional 205,241 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of analyst reports. Zacks Research lowered shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. UBS Group lifted their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Finally, Stifel Nicolaus lifted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of "Moderate Buy" and an average target price of $17.33.

Elanco Animal Health Stock Performance

ELAN stock traded up $0.08 during trading on Friday, hitting $19.18. 8,549,614 shares of the company's stock traded hands, compared to its average volume of 6,021,436. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $19.26. The stock has a fifty day moving average price of $16.68 and a two-hundred day moving average price of $13.39. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the previous year, the firm earned $0.30 earnings per share. The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.